Array/VentiRx Partner On Toll-Like Receptor Drugs In Oncology, Allergy
This article was originally published in The Pink Sheet Daily
Executive Summary
Through a licensing agreement, VentiRx gains rights to Array’s TLR program containing several development candidates
You may also be interested in...
Celgene To Collaborate With VentiRx On TRL8 Receptor Agonist For Cancer
VentiRx’s immunotherapy approach has created a compound, VTX-2337, offering potential in a variety of cancers and complementary to numerous standard-of-care backbones.
Celgene Collaborates With Array BioPharma On Cancer, Inflammation Targets
Deal does not include candidates already in Array’s pipeline, firm tells “The Pink Sheet” DAILY.
Celgene Collaborates With Array BioPharma On Cancer, Inflammation Targets
Deal does not include candidates already in Array’s pipeline, firm tells “The Pink Sheet” DAILY.